Dana-Farber Cancer Institute Joins Forces with Clinical.ly
The Dana-Farber Cancer Institute, a worldwide leader in cancer research and treatment, has partnered with Clinical.ly to enhance its regulatory operations via the Research Suite™. This collaboration marks a vital step toward optimizing the management of clinical trials.
Enhancing Clinical Trial Management
By implementing Clinical.ly's innovative eReg platform, Dana-Farber is making significant strides in improving its clinical trial management. This all-inclusive, paperless solution aims to centralize regulatory workflows, ensuring transparency and compliance throughout the clinical trial process. With a growing number of research organizations adopting Clinical.ly's offerings, Dana-Farber is leading the charge in this transformative journey.
A Major Advancement for Clinical Research
Henry Kravchenko, the CEO of Clinical.ly, expressed his enthusiasm about the partnership, saying, "We are thrilled to support Dana-Farber's clinical research operations. Our eReg platform, combined with the additional features found in the Clinical.ly Research Suite™, will empower this renowned organization, and we look forward to seeing positive results for their teams." This partnership reflects a commitment to utilizing cutting-edge tools to boost efficiency in clinical research.
Improvements in Clinical.ly Research Suite™
The Clinical.ly Research Suite™ is designed to update and streamline the various functions of clinical trials. By automating vital workflows, this suite enhances overall efficiency while ensuring better document management and oversight. Here's what the Clinical.ly Research Suite™ includes:
- eReg: An advanced electronic regulatory binder.
- eSource: A robust solution for data capture that simplifies the collection process.
- eConsent: A digital method for obtaining informed consent, which boosts participant engagement and compliance.
- ClinicallySign: eSignature functionality that meets regulatory standards.
- ClinicallyPay: A secure system for managing participant payments and reimbursements.
About Dana-Farber Cancer Institute
Established in 1947, Dana-Farber aims to provide top-notch care for both adults and children while also conducting groundbreaking research to find new cures. As a teaching affiliate of Harvard Medical School, Dana-Farber consistently ranks among the top cancer hospitals globally, dedicated to advancing knowledge and practices in cancer treatment.
About Clinical.ly
Clinical.ly focuses on delivering advanced, cloud-based technology solutions designed specifically for the clinical research industry. Their mission is to create technologies that streamline operations, reducing the burden of administrative tasks so that clinical research professionals can focus on patient care. By introducing innovative solutions, Clinical.ly seeks to enhance the efficiency of research organizations and the overall quality of clinical trials.
Frequently Asked Questions
What is the main goal of the partnership between Dana-Farber and Clinical.ly?
The partnership is focused on improving regulatory operations and streamlining clinical trial management with the help of Clinical.ly's Research Suite™.
What does Clinical.ly's eReg platform provide?
This platform offers a comprehensive, paperless solution that centralizes regulatory workflows, thereby enhancing compliance and transparency in clinical trials.
When was Dana-Farber Cancer Institute established?
Dana-Farber was founded in 1947 and has been at the forefront of cancer treatment and research ever since.
What key features are part of the Clinical.ly Research Suite™?
The Research Suite™ includes eReg, eSource, eConsent, ClinicallySign, and ClinicallyPay, all aimed at improving clinical trial processes.
How does Clinical.ly support the clinical research industry?
Clinical.ly is committed to developing technology that alleviates tedious tasks, enabling clinical research professionals to focus on patient care and enhance overall research efficiency.
